

Spa Diversity and Genetic Characterization of t127 Methicillin-resistant *Staphylococcus aureus* in a Tertiary Greek Hospital

Katerina Tsergouli

Department of Microbiology, Medical Faculty, School of Health Sciences, Aristotle University of Thessaloniki, Greece

Theodoros Karampatakis (✉ tkarampatakis@yahoo.com)

Department of Microbiology, Medical Faculty, School of Health Sciences, Aristotle University of Thessaloniki, Greece <https://orcid.org/0000-0003-0928-3193>

Konstantina Kontopoulou

Department of Microbiology, Georgios Gennimatas General Hospital of Thessaloniki, Greece

Styliani Pappa

Department of Microbiology, Medical Faculty, School of Health Sciences, Aristotle University of Thessaloniki, Greece

Parthena Kampouridou

Department of Pediatrics, Georgios Gennimatas General Hospital of Thessaloniki, Greece

Georgia Kallasidou

Department of Pediatrics, Georgios Gennimatas General Hospital of Thessaloniki, Greece

Katerina Tsiodra

Department of Microbiology, Medical Faculty, School of Health Sciences, Aristotle University of Thessaloniki, Greece

Sophia Zotos

Department of Microbiology, Georgios Gennimatas General Hospital of Thessaloniki, Greece

Eleftheria-Eugenia Farmaki

Department of Microbiology, Georgios Gennimatas General Hospital of Thessaloniki, Greece

Charalampos Kotzamanidis

Veterinary Research Institute of Thessaloniki, Greek Agricultural Organization-Dimitra, Thermi, Greece

Anna Papa

Department of Microbiology, Medical Faculty, School of Health Sciences, Aristotle University of Thessaloniki, Greece

Research Article

Keywords: Methicillin-resistant *Staphylococcus aureus*, whole-genome sequencing, spa typing

Posted Date: November 17th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-949255/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Introduction: Methicillin-resistant *Staphylococcus aureus* (MRSA) causes severe community and hospital acquired infections. Identification of staphylococcal cassette chromosome *mec* (SCC*mec*), multilocus-sequence typing, and sequencing of *S. aureus* protein A (*spa*) gene are used for MRSA typing. The aim was to investigate the *spa* types of MRSA isolates in a tertiary hospital in Greece and analyse the whole genome sequences of two t127 MRSA isolates.

Methods: Totally, 39 MRSA isolates collected during July 2019 to June 2020 in “Georgios Gennimatas” General Hospital of Thessaloniki, Greece, were included in the study. Identification and antimicrobial susceptibility testing were performed using VITEK II automated system, and *spa* typing was performed. A minimum spanning tree was used to display the *spa* type frequencies and the genetic distances among them. Two t127-MRSA isolates (IM-MRSA and PD-MRSA) were selected for WGS.

Results: Twenty-two different *spa* types were detected, with t002, t003, and t422 being the most frequent (5/39, 12.8% each), followed by t1994 (4/39, 10.3%). The isolates presented high genetic diversity and, taking into account the time between hospital admission and sampling, intrahospital spread did not occur. Even the two t127 isolates were assigned to different sequence types, ST9-XII-t127 and ST1-IVa-t127. Plasmids and genes conferring antimicrobial resistance and virulence were also identified.

Conclusions: Various *spa* types were identified and together with the information about the time between hospital admission and sampling supports polyclonal MRSA spread in the hospital excluding a nosocomial infection. WGS provides a more detailed analysis distinguishing even the isolates belonging to the same *spa* type.

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a gram-positive bacterium causing community-acquired and nosocomial infections worldwide (Tong et al. 2015). According to the latest epidemiological report of the European Centre for Disease Prevention and Control (ECDC), the prevalence of MRSA in Greece is among the highest in Europe (European Centre for Disease Prevention and Control. 2020).

Various methods are used for MRSA typing, such as the identification of staphylococcal cassette chromosome *mec* (SCC*mec*), the multilocus-sequence typing (MLST), and the sequencing of the highly polymorphic repeat region of *S. aureus* protein A (*spa*) gene (Enright et al. 2000; Bosch et al. 2016; Kaya et al. 2018). The detection of *spa*-clusters could be used as a rapid tool for the study of MRSA epidemiology in a hospital and for separation between relapse and re-infection (Satta et al. 2013).

Previous studies in Greece showed that *spa* types t044, t003 and t037 are the predominant types among MRSA isolated from clinical sources (Kachrimanidou et al. 2014; Nikolaras et al. 2019). In Europe, the most prevalent are the *spa*-types t032, t008 and t067, while t011, t108 and t034 predominate among livestock-associated (LA)-MRSA (Asadollahi et al. 2018). LA-MRSA were first detected in 2003 in pigs (Voss et al. 2005), while later, they have been isolated also in patients with no previous contact with livestock (Larsen et al. 2017). Knowledge of MRSA epidemiology is of great importance in organising and implementing infection control measures, especially in hospital settings (Leekha et al. 2020). Over the last decade, whole-genome sequencing (WGS) is an

added value for the investigation of outbreaks caused by MRSA (McManus et al. 2021). Although limited, there are reports in Greece based on whole genome MRSA sequences (Sabat et al. 2015; Sarrou et al. 2019; Karampatakis et al. 2021a; Karampatakis et al. 2021b).

The aim of the present study was to evaluate the antimicrobial resistance patterns and the distribution and prevalence of *spa* types of MRSA isolated from patients hospitalized in various wards of a tertiary hospital in Greece, and to further characterize the whole genome sequences of two isolates belonging to *spa* type t127, which is often associated with LA-MRSA.

Material And Methods

Bacterial isolates

Thirty-nine MRSA isolates collected during one-year period (July 2019 to June 2020) from 39 patients (18 males, 46%) hospitalized in various wards of “Georgios Gennimatas” General Hospital of Thessaloniki in Greece, were included in the study. The median age of the patients was 59 years (range 0.25 - 91 years). The isolates were recovered from wound (18, 46.2%), ear swab (five, 12.8%), blood, throat and nasal swabs (four, 10.3% each), central intravenous catheter (two, 5.1%), urine and eye swab samples (one, 2.5%, each) (Table 1). Eight isolates (20.5%) were taken through testing for colonization, while 29 (79.5%) were collected from infection sites. The distinction between infection and colonization was performed using previously described criteria (Geladari et al. 2017). The time between patients’ admission to the hospital and sampling was estimated in order to associate or not with nosocomial infection (>48 or <48 hours, respectively) (Table 1).

Microbiological methods

All samples were cultured in blood agar, and strain identification and antimicrobial susceptibility testing were performed using the GP ID and AST-P659 cards in VITEK II automated system, respectively (BioMérieux, Marcy l’Étoile, France). The minimum inhibitory concentration (MIC) was interpreted according to the Clinical and Laboratory Standards Institute (CLSI) breakpoints reported in January 2019 (CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement M100-S29. CLSI. Wayne). MRSA isolates were defined as resistant to oxacillin (Lee et al. 2018). Cefoxitin-screen test in VITEK 2 was used as a surrogate marker for the detection of *mecA* gene (John et al. 2009).

DNA extraction – Spa typing

DNA was extracted using the DNA extraction kit (Qiagen, Hilden, Germany). The *spa* gene was amplified and sequenced. Typing was performed through the Ridom Spa server (spaserver.ridom.de). A minimum spanning tree (MST) was generated using the *spa*-clustering method of the *spa*-typing plugin of BioNumerics v.7.1 software (Applied Maths, Sint-Martens-Latem, Belgium), which is connected to the SeqNet/Ridom *Spa* Server (<https://www.spaserver.ridom.de/>).

Whole genome sequencing - Bioinformatic analysis

Since t127 is often related with LA-MRSA, two t127 isolates [one collected from a patient hospitalized in internal medicine (IM-MRSA), and a second one from a patient hospitalized in the pediatric ward (PD-MRSA)] were selected for WGS analysis. WGS was performed on Ion Torrent PGM Platform (Life Technologies Corporation,

Grand Island, NY, USA). All procedures were conducted according to manufacturer's guidelines. PCR products were loaded on Ion-316TM chip kit V2BC. The Ion PGM Hi-Q (200) chemistry (Ion PGM Hi-Q Sequencing kit, A25592) was applied.

The consensus sequence was taken using *S. aureus* strain WHC09 (GenBank accession number CP077755) as reference sequence. MLST analysis was performed using the web-based MLST-DTU tool (Larsen et al. 2012). Resfinder version 4.1 and the Comprehensive Antibiotic Resistance Database (CARD) were used for the detection of antimicrobial resistance genes (Alcock et al. 2020; Bortolaia et al. 2020), while the virulence genes were detected using the Virulence Finder v. 2.0 software (Joensen et al. 2014). The SCCmec elements of the isolates were identified through the SCCmecFinder database version 1.2 (Kaya et al. 2018). PlasmidFinder version 2.1 was used for the identification of plasmids (Carattoli et al. 2014).

Results

Antimicrobial resistance

The antimicrobial resistance patterns are seen in Table 1. Specifically, 18 isolates (46.2%) displayed resistance to fusidic acid, 16 (41%) to levofloxacin, seven (17.9%) to tetracycline, six (15.4%) to mupirocin, five (12.8%) to trimethoprim/ sulfamethoxazole, three (7.7%) to vancomycin and two (5.1%) to teicoplanin. Thirty-seven isolates (94.9%) were resistant to cefoxitin (cefoxitin-screen positive); two isolates (5.1%) were resistant to cefoxitin and sensitive to oxacillin, while one isolate (2.6%) was sensitive to cefoxitin and resistant to oxacillin.

Spa typing

Twenty-two different *spa* types were detected, with t002, t003, and t422 being the most frequent (5/39, 12.8% each), followed by t1994 (4/39, 10.3%), t127 and t328 (2/39, 5.1% each) (Table 1). Different *spa* types were detected in the various wards, except the paediatric ward where t1994 (3/4, 75%) predominated. Most of the samples were taken <48h after admission; this was the case also for the t1994 isolates, suggesting that they were not associated with nosocomial infection (Table 1, Figure 1).

Table 1

Characteristics of the 39 MRSA strains included in the study

ID	Sex	Age (years)	Sample	Colonization /Infection	Ward	Isolation Date	>48h	Spa type	Antimicrobial Resistance Profile
1	F	59	CVC	Infection	Cardiology	May 2020	YES	t653	Ox-Fox-Fu-E
2	F	45	urine	Infection	ER	Apr 2020	NO	t442	Ox-Fox-Fu-Le-Mu-Sxt-G
3	F	72	throat swab	Colonization	ICU	May 2020	NO	t2986	Ox-Fox
4	F	81	throat swab	Colonization	ICU	Jun 2020	NO	t008	Ox-Fox-Le-E
5	F	70	throat swab	Colonization	Internal medicine	Sept 2019	NO	t422	Ox-Fox-Fu-Le-E
6	M	78	blood	Infection	Internal medicine	Dec 2019	NO	t267	Ox-Fox-Fu
7	M	91	blood	Infection	Internal medicine	Jan 2020	NO	t328	Ox-Fox-Le
8	F	82	throat swab	Colonization	Internal medicine	Apr 2020	NO	t003	Ox-Fox-Fu-Le-Tet-E
9	M	84	wound	Infection	Internal medicine	Apr 2020	NO	t127	Ox-Fox-Tet-E
10	M	75	wound	Infection	Internal medicine	Jun 2020	NO	t002	Ox-Fox-Le-E
11	F	55	nasal swab	Colonization	Orthopaedic	Jul 2019	YES	t5452	Ox-Fox-E
12	F	86	wound	Infection	Orthopaedic	Nov 2019	YES	t003	Ox-Fox
13	M	62	wound	Infection	Orthopaedic	Nov 2019	YES	t002	Ox-Fox
14	M	84	wound	Infection	Orthopaedic	Dec 2019	NO	t003	Ox-Fox-Fu-Le
15	M	79	nasal swab	Colonization	Orthopaedic	Jan 2020	YES	t002	Ox-Fox
16	F	65	wound	Infection	Outpatient	Sept 2019	NO	t422	Ox-Fox-Fu-Le-Mu-Sxt-E-G
17	M	70	wound	Infection	Outpatient	Oct 2019	NO	t440	Ox-Fox-Va-Teic
18	F	47	ear swab	Infection	Outpatient	Oct 2019	NO	t084	Fox-Sxt

19	F	28	ear swab	Infection	Outpatient	Oct 2019	NO	t422	Ox-Fox-Fu-Le
20	F	0,5	wound	Infection	Outpatient	Jan 2020	NO	t328	Ox-Fox
21	M	0,42	wound	Infection	Outpatient	Jan 2020	NO	t1814	Ox-Fox-Sxt
22	M	0,25	ear swab	Infection	Outpatient	Apr 2020	NO	t131	Ox-Fox-Fu-Tet
23	F	73	ear swab	Infection	Outpatient	May 2020	NO	t422	Ox-Fox-Le-E
24	F	7	nasal swab	Colonization	Outpatient	Jun 2020	NO	t1994	Ox-Fox-Fu-Mu-E
25	M	11	ear swab	Infection	Outpatient	Jun 2020	NO	t012	Ox-Fox-E
26	F	0,83	wound	Infection	PD	Jul 2019	NO	t1994	Fox-Fu-Mu-E
27	F	0,42	wound	Infection	PD	Jul 2019	NO	t127	Ox-Fox-Tet-E
28	M	4	eye swab	Infection	PD	Oct 2019	NO	t1994	Ox-Fox-Fu-Mu-Va
29	F	0,58	nasal swab	Colonization	PD	Nov 2019	NO	t1994	Ox-Fox-Fu-Mu
30	F	59	wound	Infection	Surgery	Aug 2019	YES	t002	Ox-Fox-Fu-Le-E
31	M	40	blood	Infection	Surgery	Sept 2019	YES	t002	Ox-Fu
32	F	21	wound	Infection	Surgery	Oct 2019	NO	t091	Ox-Fox-Fu-Le-Tet-Sxt-Va-Teic
33	M	65	wound	Infection	Surgery	Nov 2019	YES	t726	Ox-Fox
34	M	22	wound	Infection	Surgery	Mar 2020	NO	t1309	Ox-Fox-Le
35	M	16	wound	Infection	Surgery	Mar 2020	NO	t044	Ox-Fox-Fu-Tet
36	F	28	CVC	Infection	Surgery	Mar 2020	NO	t034	Ox-Fox-Tet
37	F	59	wound	Infection	Surgery	Jun 2020	NO	t003	Ox-Fox-Le-E
38	M	81	blood	Infection	Urology	Aug 2019	NO	t422	Ox-Fox-Fu-Le-E
39	M	45	wound	Infection	Urology	Feb 2020	NO	t003	Ox-Fox-E

M: Male, F: Female, CVC: Central Venous Catheter, ER: Emergency Room, ICU: Intensive Care Unit, PD: Paediatric ward

Ox: Oxacillin, Fox: Cefoxitin, Fu: Fusidic acid, Le: Levofloxacin, Mu: Mupirocin, Teic: Teicoplanin,

Te: Tetracycline, SXT: Trimethoprim/Sulfamethoxazole, G: Gentamicin, Va: Vancomycin

*Erythromycin susceptibility results for strains with ID 6,7,12-15,17-21,28,29, and 31-33 are not available.

Analysis of whole genome sequences

IM-MRSA and PD-MRSA isolates were assigned to ST9 and ST1, respectively. They were carrying *SCCmec* elements belonging to XII and IVa types, respectively.

The antimicrobial resistance and virulence genes, and the plasmids carried by the two isolates are seen in Table 2. Specifically, both had antimicrobial resistance genes for β-lactams (*mecA* and *blaZ*), aminoglycosides [*aph(3')-IIIa*], and macrolide, lincosamide and streptogramin B (*ermC*); IM-MRSA carried three additional aminoglycoside resistance genes [*ant(6)-Ia*, *aadD* and *aac(6')-aph(2')*], while PD-MRSA harbored one additional aminoglycoside resistance gene [*aad(6)*]; *dfrG* gene conferring resistance to trimethoprim was detected only in IM-MRSA. Both isolates carried several efflux pump protein genes conferring resistance to streptogramin A, tetracycline, fluoroquinolones, cephalosporins and lincosamides.

Regarding plasmid content, IM-MRSA carried a plasmid replicon type *rep22* (of the pGSA11 group), while PD-MRSA transferred plasmid replicon types *rep7a* (of the pGSA2 group, which includes the *repC* cassette), *rep7c*, *rep10* (of the pGSA3 group which includes the *ermC* gene) and *rep5* along with *rep16* (of the pGSA22 group which includes the *blaZ* gene) (Table 2).

Table 2

Genetic characteristics of two t127 MRSA strains of the study.

	PD-MRSA	IM-MRSA
Size (bp)	2,971,258	2,849,316
GC content (%)	34.2	31.0
Number of contigs (with PEGs)	530	5,636
MLST	ST1	ST9
SCCmec element	IVa	XII
Antimicrobial resistance genes	<i>mecA, blaZ,</i> <i>aad(6), aph(3')-IIIa,</i> <i>ermC,</i>	<i>mecA, blaZ, ,</i> <i>ant(6)-la, aph(3')-</i> <i>IIIa,</i> <i>aadD, aac(6')</i> <i>aph(2"),</i> <i>dfrG, ermC</i>
Efflux pump genes	<i>mepR, norA, mgrA, arlR, arlS,</i> <i>LmrS, tet(45)</i>	<i>tetL, fexA, IsaE,</i> <i>InuB</i>
Plasmid group (rep family)	pGSA ₂ (rep7) pGSA ₃ (rep10) pGSA ₂₂ (rep5, rep16)	pGSA ₁₁ (rep22)
Virulence factor (gene)		
Chemotaxis inhibitory protein (<i>chp</i>)	-	-
Aureolysin (<i>aur</i>)	+	+
Serine protease (<i>spIA, spIB</i>)	+	-
Staphylococcal complement inhibitor (<i>scn</i>)	+	-
Staphylokinase (<i>sak</i>)	+	-
γ-hemolysin (<i>hlgA, hlgB, hlgC</i>)	+	+
Other leukocidin components (<i>lukAB, lukED</i>)	+ (<i>lukED</i>)	-
Staphylococcal enterotoxin	+ (<i>seh</i>)	+ (<i>sei, sem, seo, seu</i>)
Antiseptic resistance genes (<i>qacA, qacB, qacC, qacD</i>)	-	+ (<i>qacC, qacD</i>)

Discussion

The present study provides an insight into the distribution of MRSA isolates of various *spa* types in a tertiary hospital in Greece. Most of the isolates were collected from infection sites and few from colonization sites; however, colonization usually precedes infection (Love et al. 2020). It was shown that most isolates were resistant to several antimicrobial categories. The high resistance to fusidic acid (46.2%) exceeds by far that observed among MRSA globally (2.6%) (Hajikhani et al. 2021). The resistance rate to mupirocin (15.4%) was higher than the 3.1% revealed in a previous multicenter surveillance study (Kresken et al. 2004); this is of crucial importance since resistance to mupirocin could potentially diminish the efficacy of MRSA decolonizing strategies (Bes et al. 2021). For both antimicrobials (fusidic acid and mupirocin) further studies are needed to elucidate the genetic background of the increased resistance (whether it is due to mutation(s) and/or acquired resistance genes). In contrast, resistance to levofloxacin was lower than that reported in a recently published study (17.9% versus 87.9%) (Antonelli et al. 2019); further analysis is needed. The resistance rates of vancomycin and teicoplanin were low; although infections caused by vancomycin-resistant MRSA have been described (Cong et al. 2020), resistance to vancomycin and teicoplanin are rarely identified in MRSA strains, and they remain active against MRSA causing severe infections (Beibei et al. 2010; Chen et al. 2018).

In total, 22 different *spa* types were identified, and most of them (16/22, 72.7%) were represented as singletons, suggesting a non-clonal MRSA distribution (Table 1, Figure 1). An exception was the t1994 predominance in the paediatric ward during a four-months' time period; however, it seems that it was not associated with intra-hospital infection since the time of sampling was <48h from the admission to the hospital. The high prevalence of t002 and t003 *spa* types seen in the present study, has been reported in recent studies (Engelthaler et al. 2013; Tkadlec et al. 2021), while the rare t422 type has been previously reported also in another hospital in Thessaloniki (Kachrimanidou et al. 2014).

Since t127 type is usually associated with LA-MRSA, and it has been recently detected in Greek workers in the dairy production chain (Karampatakis et al. 2021b), two t127 MRSA isolates (IM-MRSA and PD-MRSA) of the present study were selected for analysis of their whole genome. The two isolates differed each other, as IM-MRSA was assigned to ST9-XII type, while PD-MRSA to ST1-IVa type as was the case in a previous study (Karampatakis et al. 2021b). The two t127 MRSA isolates transferred the γ -hemolysin genes *hlgA*, *hlgB*, *hlgC* and aureolysin *aur* gene, which have been previously described in both ST1-IVa and ST9-XII MRSA (Cortes et al. 2017; Yu et al. 2021). PD-MRSA carried the enterotoxin *seh* gene and the gene encoding leukocidin *lukED*, as previously described in ST1-IVa MRSA isolates (Shukla et al. 2010; Cortes et al. 2017). IM-MRSA lacked leucocidin components, however it carried the enterotoxin *sei*, *sem*, *seo*, *seu* genes, although enterotoxin genes are usually absent in ST9-XII MRSA isolates (Yu et al. 2021).

LA-MRSA lack the human evasion genes *scn* (staphylococcal complement inhibitor), *chp* (chemotaxis inhibitory protein) and *sak* (staphylokinase), due to loss of the related φ Sa3 phage (Price et al. 2012). IM-MRSA lacked these three genes, while PD-MRSA lacked only the *chp* gene. IM-MRSA was isolated from wound infection and was assigned to ST9-XII, which, due to loss of *scn*, *chp* and *sak* genes, is considered to have been evolved from human to animal host (Yu et al. 2021). ST9-XII is rarely reported as cause of infection (Jin et al. 2020). *Spa*-type t127 has not been reported for *S. aureus* ST9 so far. Since generation of this *spa*-type from the repeat *spa* sequences observed in this clonal lineage would need several genetic events (mutations, deletion(s), insertion), the most probable mechanism seems to be the acquisition of the chromosomal sequence which contains *spa* from a ST9 donor; there are several examples for nontypical *spa* types for particular STs based on this genetic event, e.g. *spa* type t030 in MRSA ST239 (Monecke et al. 2018). Comparative studies are needed to confirm

which mechanism(s) took place. The second t127 isolate, PD-MRSA, was isolated from an axillary abscess and belonged to ST1-IVa-t127, which is originally considered a human-associated lineage. ST1-t127 isolates have been reported as one of the most frequent types isolated from human samples (Monaco et al. 2013).

Conclusions

The current study provides an insight into the *spa* types of MRSA in a tertiary hospital in Greece and together with the information of time interval between admission and sampling suggests polyclonal introductions in the various wards. The extensive resistance to most antimicrobial classes needs further attention since it is associated with high antimicrobial consumption. A more detailed genetic characterization is gained when WGS is applied, as shown by the results of the analysis of the two t127 MRSA isolates, which showed that although they belonged to the same *spa* type, they were different strains. Molecular surveillance studies are of high priority in the hospitals since they can lead the design of guidelines and infection control measures that must be applied to reduce and prevent the spread of MRSA.

Genome Sequences

The whole genome sequences of IM-MRSA and PD-MRSA were submitted to European Nucleotide Archive (ENA) under the study PRJEB47007 and received the Accession numbers ERS7262952 and ERS7262953, respectively.

Declarations

Funding

This work was financially supported by the European Union's Horizon 2020 project VEO (grant number 874735).

Conflicts of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Availability of data and material

Available upon request

Code availability

Not applicable

Ethics approval

Not applicable

Authors' contribution

All authors have equally contributed to the study and preparation of the manuscript.

Consent to participate

Not applicable

Consent for publication

Not applicable

References

1. (European Centre for Disease Prevention and Control. 2020) Antimicrobial resistance in the EU/EEA (EARS-Net) -Annual Epidemiological Report 2019. In: Control, ECfDPA (eds).ECDC, Stockholm
2. Alcock BP et al (2020) CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res* 48:517–525
3. Antonelli A et al (2019) Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates. *J Antimicrob Chemother* 74:3453–3461
4. Asadollahi P et al (2018) Distribution of the Most Prevalent Spa Types among Clinical Isolates of Methicillin-Resistant and -Susceptible Staphylococcus aureus around the World: A Review. *Front Microbiol* 9:163
5. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W (2010) Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. *Int J Antimicrob Agents* 35:3–12
6. Bes TM et al (2021) Susceptibility to chlorhexidine and mupirocin among methicillin-resistant Staphylococcus aureus clinical isolates from a teaching hospital. *Rev Inst Med Trop Sao Paulo* 63:e27
7. Bortolaia V et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75:3491–3500
8. Bosch T et al (2016) Changing characteristics of livestock-associated meticillin-resistant Staphylococcus aureus isolated from humans - emergence of a subclade transmitted without livestock exposure, the Netherlands, 2003 to 2014. *Euro Surveill* 21 doi: 10.2807/1560-7917.ES.2016.21.21.30236
9. Carattoli A et al (2014) In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903
10. Chen H et al (2018) Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis. *J Infect Dev Ctries* 11:926–934
11. CLSI (2019) Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement M100-S29. CLSI. Wayne PA, USA;

12. Cong Y, Yang S, Rao X (2020) Vancomycin resistant *Staphylococcus aureus* infections: A review of case updating and clinical features. *J Adv Res* 21:169–176
13. Cortes MF et al (2017) Complete genome sequence of community-associated methicillin-resistant *Staphylococcus aureus* (strain USA400-0051), a prototype of the USA400 clone. *Mem Inst Oswaldo Cruz* 112:790–792
14. Engelthaler DM et al (2013) Rapid and robust phylotyping of spa t003, a dominant MRSA clone in Luxembourg and other European countries. *BMC Infect Dis* 13:339
15. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* 38:1008–1015
16. Geladari A et al (2017) Epidemiological surveillance of multidrug-resistant gram-negative bacteria in a solid organ transplantation department. *Transpl Infect Dis* 19 doi: 10.1111/tid.12686
17. Hajikhani B et al (2021) The global prevalence of fusidic acid resistance in clinical isolates of *Staphylococcus aureus*: a systematic review and meta-analysis. *Antimicrob Resist Infect Control* 10:75
18. Jin Y et al (2020) Characterization of highly virulent community-associated methicillin-resistant *Staphylococcus aureus* ST9-SCCmec XII causing bloodstream infection in China. *Emerg Microbes Infect* 9:2526–2535
19. Joensen KG et al (2014) Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J Clin Microbiol* 52:1501–1510
20. John MA et al (2009) Comparison of three phenotypic techniques for detection of methicillin resistance in *Staphylococcus* spp. reveals a species-dependent performance. *J Antimicrob Chemother* 63:493–496
21. Kachrimanidou M et al (2014) Prevalence and molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in a tertiary Greek hospital. *Hippokratia* 18:24–27
22. Karampatakis T et al (2021a) Genetic characterization of livestock-associated methicillin-resistant *Staphylococcus aureus* isolated in Greece. *Braz J Microbiol* doi: 10.1007/s42770-021-00587-z
23. Karampatakis T, Papadopoulos P, Tsergouli K, Angelidis AS, Sergelidis D, Papa A (2021b) Genetic characterization of two methicillin-resistant *Staphylococcus aureus* spa type t127 strains isolated from workers in the dairy production chain in Greece. *Acta Microbiol Immunol Hung* doi: 10.1556/030.2021.01460
24. Kaya H et al (2018) SCCmecFinder, a Web-Based Tool for Typing of Staphylococcal Cassette Chromosome mec in *Staphylococcus aureus* Using Whole-Genome Sequence Data. *mSphere* 3 doi: 10.1128/mSphere.00612-17
25. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, Paul-Ehrlich-Society for C (2004) Prevalence of mupirocin resistance in clinical isolates of *Staphylococcus aureus* and *Staphylococcus epidermidis*: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. *Int J Antimicrob Agents* 23:577–581
26. Larsen J et al (2017) Emergence of Livestock-Associated Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections in Denmark. *Clin Infect Dis* 65:1072–1076
27. Larsen MV et al (2012) Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol* 50:1355–1361
28. Lee AS et al (2018) Methicillin-resistant *Staphylococcus aureus*. *Nat Rev Dis Primers* 4:18033

29. Leekha S, O'Hara LM, Sbarra A, Li S, Harris AD (2020) Comparison of surveillance and clinical cultures to measure the impact of infection control interventions on the incidence of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant *Enterococcus* in the hospital. *Infect Control Hosp Epidemiol* 41:161–165
30. Love NK, Pichon B, Padfield S, Hughes GJ (2020) A persistent recurring cluster of meticillin-resistant *Staphylococcus aureus* (MRSA) colonizations in a special care baby unit: a matched case-control study. *J Hosp Infect* 106:774–781
31. McManus BA et al (2021) Multiple distinct outbreaks of Panton-Valentine leucocidin-positive community-associated meticillin-resistant *Staphylococcus aureus* in Ireland investigated by whole-genome sequencing. *J Hosp Infect* 108:72–80
32. Monaco M, Pedroni P, Sanchini A, Bonomini A, Indelicato A, Pantosti A (2013) Livestock-associated methicillin-resistant *Staphylococcus aureus* responsible for human colonization and infection in an area of Italy with high density of pig farming. *BMC Infect Dis* 13:258
33. Monecke S et al (2018) Molecular Typing of ST239-MRSA-III From Diverse Geographic Locations and the Evolution of the SCCmec III Element During Its Intercontinental Spread. *Front Microbiol* 9:1436
34. Nikolaras GP et al (2019) Changes in the rates and population structure of methicillin-resistant *Staphylococcus aureus* (MRSA) from bloodstream infections: A single-centre experience (2000-2015). *J Glob Antimicrob Resist* 17:117–122
35. Price LB et al (2012) *Staphylococcus aureus* CC398: host adaptation and emergence of methicillin resistance in livestock. *mBio* 3 doi: 10.1128/mBio.00305-11
36. Sabat AJ, Pournaras S, Akkerboom V, Tsakris A, Grundmann H, Friedrich AW (2015) Whole-genome analysis of an oxacillin-susceptible CC80 *mecA*-positive *Staphylococcus aureus* clinical isolate: insights into the mechanisms of cryptic methicillin resistance. *J Antimicrob Chemother* 70:2956–2964
37. Sarrou S et al (2019) MLSB-Resistant *Staphylococcus aureus* in Central Greece: Rate of Resistance and Molecular Characterization. *Microb Drug Resist* 25:543–550
38. Satta G, Ling CL, Cunningham ES, McHugh TD, Hopkins S (2013) Utility and limitations of Spa-typing in understanding the epidemiology of *Staphylococcus aureus* bacteraemia isolates in a single University Hospital. *BMC Res Notes* 6:398
39. Shukla SK et al (2010) Virulence genes and genotypic associations in nasal carriage, community-associated methicillin-susceptible and methicillin-resistant USA400 *Staphylococcus aureus* isolates. *J Clin Microbiol* 48:3582–3592
40. Tkadlec J et al (2021) The molecular epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) in the Czech Republic. *J Antimicrob Chemother* 76:55–64
41. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr (2015) *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 28:603–661
42. Voss A, Loeffen F, Bakker J, Klaassen C, Wulf M (2005) Methicillin-resistant *Staphylococcus aureus* in pig farming. *Emerg Infect Dis* 11:1965–1966
43. Yu F et al (2021) Molecular Evolution and Adaptation of Livestock-Associated Methicillin-Resistant *Staphylococcus aureus* (LA-MRSA) Sequence Type 9. *mSystems* 6:e0049221

Figures




Figure 1

Minimum spanning tree based on spa-typing results of MRSA strains depending on the department of isolation. Each spa type is represented by a single node. The size of the node depends proportionally on the number of strains within the spa type. The colored sections represent a different ward. The distance between nodes represents the genetic diversity of the isolates.